Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Junwei Dou"'
Autor:
Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You, Zhengyu Jiang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 7, Pp 2990-3005 (2022)
The proteolysis targeting chimeras (PROTACs) technology has been rapidly developed since its birth in 2001, attracting rapidly growing attention of scientific institutes and pharmaceutical companies. At present, a variety of small molecule PROTACs ha
Externí odkaz:
https://doaj.org/article/11d524be00014077824fab0a24355cff
Autor:
Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You, Zhengyu Jiang
Publikováno v:
Acta pharmaceutica Sinica. B. 12(7)
The proteolysis targeting chimeras (PROTACs) technology has been rapidly developed since its birth in 2001, attracting rapidly growing attention of scientific institutes and pharmaceutical companies. At present, a variety of small molecule PROTACs ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ccd3bb8cf2bdbcc8c7af52eea410f9
https://pubmed.ncbi.nlm.nih.gov/35865099
https://pubmed.ncbi.nlm.nih.gov/35865099
Publikováno v:
European journal of medicinal chemistry. 220
The Bcl-2 family members rigorously regulate cell endogenous apoptosis, and targeting anti-apoptotic members is a hot topic in design of anti-cancer drugs. At present, FDA and EMA have approved Bcl-2 inhibitor Venetoclax (ABT-199) for treating chroni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e47e329bb7afc0a6b0344a4cb0bedaf5
https://pubmed.ncbi.nlm.nih.gov/34034128
https://pubmed.ncbi.nlm.nih.gov/34034128